Ryan Fiehler

Ryan Fiehler

Company: F-Star Therapeutics

Job title: Associate Director, Discovery


1:15 pm Next Generation Tetravalent Bispecific Antibodies for Cancer Immunotherapy 1:15 pm

Discover F-star’s unique approach to making bispecific tetravalent antibodies in the Fc Description of the process to produce a conditional CD137 agonist Fcab FS222 bispecific uses of the CD137 agonist Fcab, in combination with a PD-L1 targeting Fab Discuss the benefits of FS222 in being tetravalentRead more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.